Keywords: UCB, Biotie Theapies, Tozadenant, Parkinson's disease, Global rights
UCB licenses global rights to tozadenant in Parkinson's disease from Biotie
Article | 27 February 2013
Finland-based Biotie Therapies (Nasdaq-OMX: BTH1V) says that UCB (Euronext Brussels; UCB), Belgium’s largest drugmaker, has licensed worldwide ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
